Genetic mapping

Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU Langone Health

Retrieved on: 
Tuesday, August 3, 2021

This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.

Key Points: 
  • This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.
  • The number of genes cancer types assayed is the largest among academic genomic sequencing tests of its kind.
  • Philips Genomics Workspace, hosted on cloud-based Philips HealthSuite, will help facilitate the integration into the EMR so tests can be seamlessly ordered, reviewed, and shared by a patients care team.
  • With Philips Genomics Workspace, oncologists can map a patients uniquecharacteristics to a therapy that is best suited for them and provide evidence on why that therapy is preferable.

Element Biosciences Bolsters Leadership Team to Advance Development and Commercialization of DNA Sequencing Platform

Retrieved on: 
Tuesday, July 20, 2021

The new leadership appointments follow the recent close of $276 million in Series C financing and support the companys growth and strategic plans for the development and commercialization of a disruptive DNA sequencing platform.

Key Points: 
  • The new leadership appointments follow the recent close of $276 million in Series C financing and support the companys growth and strategic plans for the development and commercialization of a disruptive DNA sequencing platform.
  • We are focused on growing a team that is both deeply passionate about reimagining DNA sequencing and believes in our mission to dramatically expand access to high quality, low cost, easy-to-use genomics tools.
  • She joins Element from MULTI, INC, a global provider of advanced medical imaging solutions, where she served as Chief Business Development Officer.
  • Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets.

Pacific Biosciences of California, Inc. Second Quarter 2021 Financial Results Call

Retrieved on: 
Monday, July 19, 2021

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Key Points: 
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.
  • The companys innovative instruments are based on Single Molecule, Real-Time (SMRT) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Apton Biosystems Announces $24 Million Series-A Financing

Retrieved on: 
Wednesday, June 30, 2021

PLEASANTON, Calif., June 30, 2021 /PRNewswire-PRWeb/ --Apton Biosystems, Inc., a developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications, such as early cancer detection and population sequencing, today announced the close of a $24 million Series-A financing.

Key Points: 
  • PLEASANTON, Calif., June 30, 2021 /PRNewswire-PRWeb/ --Apton Biosystems, Inc., a developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications, such as early cancer detection and population sequencing, today announced the close of a $24 million Series-A financing.
  • The financing was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures.
  • Since its founding in 2012, Apton Biosystems has developed expertise in super-resolution imaging optics and consumables aimed at RNA and DNA sequencing and single-molecule proteomics.
  • Apton Biosystems, Inc., is a Pleasanton, California-based developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing.

Element Biosciences Closes $276 Million Series C Financing to Democratize Access to Genomics

Retrieved on: 
Tuesday, June 29, 2021

With this latest investment, Element Biosciences has raised approximately $400 million.

Key Points: 
  • With this latest investment, Element Biosciences has raised approximately $400 million.
  • "Element will provide researchers with innovative technology choices and more flexible tools for scientific exploration," said Molly He, Ph.D., co-founder and chief executive officer of Element Biosciences.
  • "We are working to realize our vision of dramatically expanding access to high quality, low cost, easy-to-use genomics tools."
  • Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets.

Intelliseq Launches IntelliseqFlow, The First Cloud-based Platform That Translates Raw DNA Data Into Complete Reports With Clinical Insights

Retrieved on: 
Thursday, June 24, 2021

Intelliseq , a genome-analyzing technology provider, today announced the launch of IntelliseqFlow, a unique SaaS platform for raw NGS data analysis with diverse genomic applications.

Key Points: 
  • Intelliseq , a genome-analyzing technology provider, today announced the launch of IntelliseqFlow, a unique SaaS platform for raw NGS data analysis with diverse genomic applications.
  • The platform offers a comprehensive analysis of genetic data and generates full reports with clinical insights.
  • IntelliseqFlow benefits from a team with deep knowledge in genome informatics who are known for their published peer-reviewed scientific research.
  • The process of human genome analysis can be the slowest, most expensive, and labor-intensive one among all the processes around DNA.

GenapSys™ Announces Additions to the Company's Executive Team

Retrieved on: 
Thursday, June 24, 2021

REDWOOD CITY, Calif., June 24, 2021 /PRNewswire/ -- GenapSys, Inc. (GenapSys), a company developing a highly accurate and scalable electronic sequencing platform, today announced the additions of Britton Russell, Mary Stewart, and Surekha Karudapuram to its executive team.

Key Points: 
  • REDWOOD CITY, Calif., June 24, 2021 /PRNewswire/ -- GenapSys, Inc. (GenapSys), a company developing a highly accurate and scalable electronic sequencing platform, today announced the additions of Britton Russell, Mary Stewart, and Surekha Karudapuram to its executive team.
  • "We are pleased to welcome Britton, Mary, and Surekha to our growing team," said Jason Myers, Ph.D., Chief Executive Officer of GenapSys.
  • "Their deep set of leadership experiences will strengthen the GenapSys executive team and provide valuable insight as we accelerate development of our silicon chip-based genomic sequencing ecosystem.
  • "Jason and the team at GenapSys are building a groundbreaking company that is poised to change healthcare with a flexible and automated NGS solution.

Australian Genomic Sequencing Leader Accelerates Research with Cloudian

Retrieved on: 
Monday, June 21, 2021

With facilities across Australia, AGRF empowers world-class genomic science in the biomedical, clinical, agricultural and environmental sectors, with over 15,000 clients worldwide.

Key Points: 
  • With facilities across Australia, AGRF empowers world-class genomic science in the biomedical, clinical, agricultural and environmental sectors, with over 15,000 clients worldwide.
  • The organization has been at the center of essential COVID-19 research, from assisting researchers with vaccine development to detecting the virus in wastewater.
  • AGRF is also distinguishing itself by playing a role in sequencing genomes of Australian threatened species to aid conservation efforts.
  • The adoption of the Cloudian solution has brought huge benefits to the leading sequencing provider.

GenapSys™ Appoints Three New Members to its Board of Directors

Retrieved on: 
Thursday, June 10, 2021

"I am delighted to welcome our new Board members during this exciting phase of transformation and growth for GenapSys," said Jason Myers, Ph.D., Chief Executive Officer of GenapSys.

Key Points: 
  • "I am delighted to welcome our new Board members during this exciting phase of transformation and growth for GenapSys," said Jason Myers, Ph.D., Chief Executive Officer of GenapSys.
  • "I am excited to join GenapSys as the Company's goals align with my passion to transform healthcare through technology that provides accessible genomic sequencing," commented Diana McKenzie.
  • "Next-generation sequencing holds tremendous promise and GenapSys is pioneering a unique approach with an aspiration to unlock its full potential.
  • Loretta Cecil brings 36 years oflegal and compliance leadership to GenapSys, with a wide range of proven expertise in corporate governance.

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature

Retrieved on: 
Thursday, June 10, 2021

The method, called Micro Capture-C (MCC), was invented in the laboratories of Nucleomes academic founders at the University of Oxford, and maps the 3D genome structure at unprecedented single base pair resolution.

Key Points: 
  • The method, called Micro Capture-C (MCC), was invented in the laboratories of Nucleomes academic founders at the University of Oxford, and maps the 3D genome structure at unprecedented single base pair resolution.
  • Our new method offers a significant advantage by detecting DNA interactions at base pair resolution.
  • Dr Danuta Jeziorska, Chief Executive Officer & Co-Founder of Nucleome, added: 3D genome analysis is key to understanding the largely untapped dark matter of the genome.
  • Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease.